logo of the vendor
Pharma Intelligence UK Ltd logo

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations

thumbnail of content

As technology advances and innovations like digital endpoints and biomarkers become more prevalent, regulatory considerations surrounding them become more complex. Navigate this evolving space, with insights from this free webinar.

Experts from Biofourmis will share their insights into:

  • Traditional vs. digital measures in clinical research and their key differences.
  • Regulatory framework for digital biomarkers and endpoints, including regional disparities.
  • Regulatory considerations for data integrity and security, validation and reliability, and patient safety and privacy.
  • Integrating digital biomarkers and endpoints into trial protocols.
  • Emerging and current regulatory trends and future regulatory direction.

Sign up to our content service and access now

Opt In?